Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

TNC/Kg and CD34+/Kg Cell Dose Impact on Patient Engraftment after Allogeneic Transplant with Conventional Bone Marrow; Better Predictability of Graft Content Needed

Eric Davis, Elise Feuer, Candice Rapoport, Stephanie Lobaugh, Sean M. Devlin, Anne Archer, Stephanie Chinapen, Jacob Federman, Amanda Kelly, Elizabeth Klein, Melissa Nhaissi, Deborah Wells, Juliet N Barker, Esperanza B. Papadopoulos, Andromachi Scaradavou, Jaap Jan Boelens, Miguel-Angel Perales, Elena Maryamchik, Roni Tamari

Blood (2023) 142 (Supplement 1): 113.

https://doi.org/10.1182/blood-2023-190940

Published: 2023

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

Ioannis Politikos, Warren B Fingrut, Samantha Brown, Stephanie Chinapen, Sean Quach, Parastoo B. Dahi, Boglarka Gyurkocza, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Roni Tamari, Miguel-Angel Perales, Andromachi Scaradavou, Juliet N Barker

Blood (2023) 142 (Supplement 1): 2209.

https://doi.org/10.1182/blood-2023-190836

Published: 2023

Journal Articles

Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial

Alina Markova, Esperanza B. Papadopoulos, Stephen Dusza, Jelena Ostojić, Rizi Ai, Tara Maier, Mario Lacouture, Roni Tamari, Boglarka Gyurkocza, Brian C. Shaffer, Michael Scordo, Miguel-Angel Perales, Andrew Harris, Doris M. Ponce

Blood (2023) 142 (Supplement 1): 777.

https://doi.org/10.1182/blood-2023-182198

Published: 2023

Journal Articles

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

Gabriela S. Hobbs, Haesook T. Kim, Suzanne O'Connor, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Areej El-Jawahri, Steven McAfee, Jessica Hem, Patricia Lozano, Jonas S. Jutzi, Ann Mullally, Yi-Bin Chen, Zachariah Defilipp

Blood (2023) 142 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2023-178645

Published: 2023

Journal Articles

Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies

Ioannis Politikos, Sean M. Devlin, Stephanie Chinapen, Sean Quach, Parastoo B. Dahi, Boglarka Gyurkocza, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Roni Tamari, Andromachi Scaradavou, Juliet N Barker

Blood (2023) 142 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2023-190528

Published: 2023

Journal Articles

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Blood (2023) 142 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2023-173441

Published: 2023

Journal Articles

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Blood (2022) 140 (Supplement 1): 2137–2139.

https://doi.org/10.1182/blood-2022-157193

Published: 2022

Journal Articles

PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)

Hillard M Lazarus, Joseph P. McGuirk, Tsila Zuckerman, Leland Metheny, Luis Pineiro, Mark R. Litzow, Scott D. Rowley, Batia Avni, Roni Tamari, Michal Sheleg, Daniel Rothenstein, Nitsan Halevy, Jacob M. Rowe

Blood (2022) 140 (Supplement 1): 10447–10448.

https://doi.org/10.1182/blood-2022-169266

Published: 2022

Journal Articles

Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes

Benjamin Kroger, Yi Huang, Prapti Patel, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Jr., Farrukh T. Awan, Praveen Ramakrishnan, Kunal Verma, Russell Vittrup, Robert H. Collins, Madhuri Vusirikala, Yazan F. Madanat, Roni Tamari, Stephen S. Chung

Blood (2022) 140 (Supplement 1): 9833–9835.

https://doi.org/10.1182/blood-2022-171179

Published: 2022

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Shlomo Elias, Moneeza Walji, Samantha Brown, Sean M. Devlin, Esperanza B. Papadopoulos, Ann A Jakubowski, Doris M Ponce, James W. Young, Sergio A Giralt, Miguel-Angel Perales, Brian C. Shaffer, Parastoo B. Dahi, Richard J. Lin, Christina Cho, Roni Tamari, Melody Smith, Boglarka Gyurkocza

Blood (2022) 140 (Supplement 1): 10627–10628.

https://doi.org/10.1182/blood-2022-170088

Published: 2022

Journal Articles

Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations

Blood (2022) 140 (Supplement 1): 4759–4761.

https://doi.org/10.1182/blood-2022-159303

Published: 2022

Journal Articles

Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy

Maria Stefania Infante, Susan DeWolf, Roni Tamari, Parastoo B. Dahi, Yeon Joo Lee, Ioannis Politikos, Juliet N. Barker, N. Esther Babady, Lakshmi Ramanathan, Susan Seo, Sergio A. Giralt, Mini Kamboj, Miguel-Angel Perales, Gunjan L. Shah

Blood (2022) 140 (Supplement 1): 4792–4794.

https://doi.org/10.1182/blood-2022-166393

Published: 2022

Journal Articles

Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT)

Asmita Mishra, Roni Tamari, Amy E. DeZern, Michael T. Byrne, Mahasweta Gooptu, Yi-Bin Chen, H. Joachim Deeg, Phillip Gallacher, Anders Wennborg, Denice Kaylor Hickman, Eyal C. Attar, Hugo F. Fernandez

Blood (2021) 138 (Supplement 1): 409.

https://doi.org/10.1182/blood-2021-147962

Published: 2021

Journal Articles

A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis

Gabriela Hobbs, Haesook T. Kim, AJ S. Bottoms, Michael T. Byrne, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Zachariah Defilipp, Areej El-Jawahri, Steven McAfee, Yi-Bin Chen

Blood (2021) 138 (Supplement 1): 169.

https://doi.org/10.1182/blood-2021-146330

Published: 2021

Journal Articles

Non-Relapse Mortality in TP53 -Mutated MDS/AML - a Multi-Center Collaborative Study

Blood (2021) 138 (Supplement 1): 2922.

https://doi.org/10.1182/blood-2021-154151

Published: 2021

Journal Articles

Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines

Roni Tamari, Ioannis Politikos, David Knorr, Santosha Vardhana, Jennifer Young, Leeann Marcello, Sital Doddi, Sean M Devlin, Lakshmi Ramanathan, Melissa S. Pessin, Erica Dunn, Meighan A. Palazzo, Christina Bravo, Genovefa A. Papanicolaou, Mini Kamboj, Miguel-Angel Perales, David J. Chung, Gunjan L Shah

Blood (2021) 138 (Supplement 1): 3891.

https://doi.org/10.1182/blood-2021-151376

Published: 2021

Journal Articles

Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137749

Published: 2020

Journal Articles

TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response

Blood (2020) 136 (Supplement 1): 21–23.

https://doi.org/10.1182/blood-2020-141018

Published: 2020

Journal Articles

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136828

Published: 2020

NARROW

TNC/Kg and CD34+/Kg Cell Dose Impact on Patient Engraftment after Allogeneic Transplant with Conventional Bone Marrow; Better Predictability of Graft Content Needed

High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)

Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations

Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy

Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT)

A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis

Non-Relapse Mortality in TP53 -Mutated MDS/AML - a Multi-Center Collaborative Study

Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines

Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy

TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only